Mill Road Eyeing Skullcandy (SKUL) Takeover; Robert W. Baird Sees Upside In Methode Electronics (MEI)

Skullcandy_SKUL

Shares of Skullcandy, Inc. (Nasdaq:SKUL) soared $1.08 (or +23.08%) to $5.76 on Friday’s trading session after the audio-tech developer agreed to be acquired by Incipio LLC for $5.75 per share in cash

Mill Road Capital II, L.P. disclosed after the closing bell in a regulatory filing ( SC 13D ) with the U.S. Securities and Exchange Commission (SEC) a 9.8%  stake (or 2,805,320 shares) in the company. According to the SEC filing, the private investment firm sent a letter to Skullcandy’s chairman with an offer to acquire it for $6.05 per share

Skullcandy, which designs, markets, and distributes audio and gaming products under the Skullcandy and Astro Gaming brands, has 28.63M Shares Outstanding, Market Capitalization (intraday) of $164.89M and SKUL stock 52-week range is from $2.75 to $8.27 per share

*

Methode_Electronics_MEI

Investment analysts at Robert W. Baird upgraded Methode Electronics, Inc. (NYSE:MEI) stock and boosted their price target from $35.00 to $45.00

MEI stock closed at $31.94, down -$0.04 (or -0.13%) with a total volume of 843,290 shares traded on Friday, representing a large increase in activity compared with its average volume (3m) of 269,028

Methode Electronics, which designs, manufactures, and markets components and subsystem devices, has 36.91M Shares Outstanding, Market Capitalization (intraday) of $1.18B and MEI stock one-year range is between $22.72 and $37.25 per share

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/

Merckle Sees Potential In CareDx (CDNA); Bullish Volatility In Biostar Pharma (BSPM)

 

http://galaxystocks.com/wp-content/uploads/2016/06/CareDx_CDNA.png

After the closing bell on Friday, Merckle International GmbH disclosed in a regulatory filing with the U.S. Securities and Exchange Commission (SEC) a 5.1% stake (1,118,830 shares) in CareDx Inc. (Nasdaq:CDNA), also indicating that it plans to acquire more – up to 20% of the shares outstanding of the molecular diagnostics company in the future

CDNA stock finished the regular session at $4.75, down $0.05 (or -1.04%) and 67,221 of its shares shares changed hands during the day

CareDx, which focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients, has 14.29M Shares Outstanding, Market Capitalization (intraday) of $67.9M and CDNA stock one-year range is between $3.70 and $8.00 per share

*

http://galaxystocks.com/wp-content/uploads/2016/06/Biostar_Pharmaceuticals_BSPM.jpg

Biostar Pharmaceuticals, Inc. (Nasdaq:BSPM) stock soared to touch the $5.59 mark in intraday trading Friday to finally close at $4.27, up $1.00 (30.58%) with a total volume of 8,608,833 shares traded during the day, representing a large increase in activity versus its average volume (3m) of 530,282.

However, there appears to be no relevant recent news from the pharmaceutical company in the street that may explain this movement in the stock

Biostar Pharmaceuticals, which develops, manufactures, and markets pharmaceutical and health supplement products in China, has 2.21M Shares Outstanding, Market Capitalization (intraday) of $9.44M and BSPM stock 52-week range is from $1.08 to $8.40 per share

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/

 

Downside Brexit-Reaction: HSBC Holdings (HSBC), Barclays (BCS), Lloyds Banking (LYG), Royal Bank of Scotland (RBS)

earth

Shares of some of the largest European banks – including HSBC Holdings, Barclays, Lloyds Banking Group and Royal Bank of Scotland Group – went into negative territory on Friday after British voters preferred to leave the European Union

*

http://galaxystocks.com/wp-content/uploads/2016/06/HSBC_Holdings_HSBC.png

HSBC Holdings plc (NYSE:HSBC) shares are trading at $31.15, down $2.58 (or -7.65%)

HSBC Holdings, which provides banking and financial products and services in the U.K. and internationally, has 19.75B Shares Outstanding and HSBC stock one-year range is from $29.14 to $46.70 per share

*

http://galaxystocks.com/wp-content/uploads/2016/06/Barclays_BCS.png

Shares of Barclays PLC (NYSE:BCS) touched a new 52-week low of $8.13 in intraday trading Friday, currently changing hands at $9.09, down $2.10 (or -18.74%)

Barclays, a British multinational banking and financial services company, has 16.81B Shares Outstanding and BCS stock new one-year range is between $8.13 and $18.05 per share

*

http://galaxystocks.com/wp-content/uploads/2016/06/Lloyds_Banking_Group_LYG.png

The price of Lloyds Banking Group plc (NYSE:LYG) stock reached a new one-year low of $3.17 during Friday’s trading session and is currently in negative territory by 22.93% (or -$1.00), trading at $3.35 per share

Lloyds Banking Group, a major British financial institution, has 71.37B Shares Outstanding and LYG stock new 52-week range is from $3.17 to $5.57 per share

*

http://galaxystocks.com/wp-content/uploads/2016/06/Royal_Bank_of_Scotland_Group_RBS.png

Royal Bank of Scotland Group plc (NYSE:RBS) stock also touched a new 52-week low of $5.70 on Friday, currently changing hands at $5.83, down -$1.66 (or -22.19%)

Royal Bank of Scotland, which provides banking and financial products and services, has 11.66B Shares Outstanding and RBS stock new 52-week renge is between $5.70 and $11.61 per share

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/

 

Emerge Energy Services (EMES) Inks Mega Sale-Deal; Oxford Immunotec (OXFD) Boosts Revenue Guidance

Emerge_Energy_Services_EMES

Shares of Emerge Energy Services LP (NYSE:EMES) soared more than 10% in the extended session Thursday as the company said that it will sell its fuels business to oil giant Sunoco LP (NYSE:SUN) for $178.5 million, adding that after the sale it will focus on its Sand segment.

EMES stock surged $0.29 (or +2.58%) to $11.51 with a total volume of 1,301,439 shares traded during the day, representing a large increase in activity versus its average volume (3m) of 845,114

Emerge Energy Services, engaged in the businesses of mining, producing, and distributing silica sand, has 24.12M Shares Outstanding, Market Capitalization (intraday) of $277.64M and EMES stock 52-week range is from $1.97 to $37.97 per share

*

Oxford_Immunotec_Global_OXFD

The price of Oxford Immunotec Global PLC (Nasdaq:OXFD) stock closed in negative territory by 2.02% (or -$0.19) at $9.20 on Thursday’s trading session

The diagnostics company has boosted its 2016 revenue guidance – as a result of its acquisition of Imugen, Inc. – by approximately $5.5 million to a range of $79.5 million to $82.5 million

Oxford Immunotec Global, focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, has 22.57M Shares Outstanding, Market Capitalization (intraday) of $207.61M and OXFD stock one-year range is between $8.45 and $14.99 per share

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/

CVD Equipment (CVV) Lands a Multi-Million Dollar Deal; Apogee Enterprises (APOG) Profit Surprises Wall Street

CVD_Equipment_CVV

Shares of CVD Equipment Corp. (Nasdaq:CVV) soared over 20% in after-hours trading Wednesday as the company said that it has secured a deal valued at about $30 million to make fiber coating systems that will be installed in the customer’s new high volume facility.

CVV stock closed the regular session in positive territory by 0.58% (or +0.04) at $6.91 with a total volume of 22,608 shares traded during the day

CVD Equipment, a provider of chemical vapor deposition systems, has 6.22M Shares Outstanding, Market Capitalization (intraday) of $42.14M and CVV stock 52-week range is between $6.25 and $13.72 per share

*

http://galaxystocks.com/wp-content/uploads/2016/06/Apogee_Enterprises_APOG.jpg

Apogee Enterprises, Inc. (Nasdaq:APOG) delivered in its financial results quarterly profit numbers above Wall Street analysts’ expectations, sending its shares up by more than 7% in the extended session Wednesday

For its first quarter fiscal 2017, Apogee posted revenues of $247.9 million, a 3% increase year over year, and net income of $17.72 million, or $0.61 per diluted share, compared to net income of $12.13 million, or $0.49 per diluted share in the same quarter the prior year, exceeding the Capital IQ Consensus Estimate of $0.49 earnings per share on revenues of $247.18 million for the period

The company raised its full-year fiscal 2017 earnings guidance to a range of $2.70 to $2.85 per share from the previously reported earnings guidance of $2.65 to $2.80 per share for the period

APOG stock finished at $41.50, down $1.83 (or -4.22%) and 542,199.00 of its shares changed hands on Wednesday

Apogee Enterprises, a leader in technologies involving the design and development of value-added glass products and services, has 28.79M Shares Outstanding, Market Capitalization (intraday) of $1.18B and APOG stock one-year range is from $33.67 to $61.05 per share

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/

The World Stock Market

CRWE WORLD Advertising Services Rate Join CRWE WORLD Affiliate Program